- Home
- TRIB vs NRSN Comparison
TRIB vs NRSN Comparison
Compare TRIB & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- NRSN
- Stock Information
- Founded
- TRIB 1992
- NRSN 2017
- Country
- TRIB Ireland
- NRSN Israel
- Employees
- TRIB N/A
- NRSN N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- NRSN Health Care
- Exchange
- TRIB Nasdaq
- NRSN Nasdaq
- Market Cap
- TRIB 25.5M
- NRSN 26.0M
- IPO Year
- TRIB N/A
- NRSN 2021
- Fundamental
- Price
- TRIB $0.53
- NRSN $1.03
- Analyst Decision
- TRIB
- NRSN Hold
- Analyst Count
- TRIB 0
- NRSN 1
- Target Price
- TRIB N/A
- NRSN N/A
- AVG Volume (30 Days)
- TRIB 40.2K
- NRSN 133.0K
- Earning Date
- TRIB 05-22-2025
- NRSN 04-07-2025
- Dividend Yield
- TRIB N/A
- NRSN N/A
- EPS Growth
- TRIB N/A
- NRSN N/A
- EPS
- TRIB N/A
- NRSN N/A
- Revenue
- TRIB $59,126,000.00
- NRSN N/A
- Revenue This Year
- TRIB $11.63
- NRSN N/A
- Revenue Next Year
- TRIB $10.13
- NRSN N/A
- P/E Ratio
- TRIB N/A
- NRSN N/A
- Revenue Growth
- TRIB N/A
- NRSN N/A
- 52 Week Low
- TRIB $0.48
- NRSN $0.51
- 52 Week High
- TRIB $3.55
- NRSN $1.73
- Technical
- Relative Strength Index (RSI)
- TRIB 37.41
- NRSN 50.00
- Support Level
- TRIB $0.51
- NRSN $1.00
- Resistance Level
- TRIB $0.60
- NRSN $1.04
- Average True Range (ATR)
- TRIB 0.05
- NRSN 0.09
- MACD
- TRIB 0.00
- NRSN 0.01
- Stochastic Oscillator
- TRIB 35.35
- NRSN 76.38
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.